PharmaTelevision - Roel Bulthuis of Merck Serono Ventures- looking for new investment opportunities in oncology, neurodegeneration, inflammation, fertility and endocrinology

Roel Bulthuis of Merck Serono Ventures- looking for new investment opportunities in oncology, neurodegeneration, inflammation, fertility and endocrinology

Episode Loading...

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Roel Bulthuis of Merck Serono Ventures- looking for new investment opportunities in oncology, neurodegeneration, inflammation, fertility and endocrinology

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks to Roel Bulthuis, Head of Merck Serono Ventures of Merck Serono SA

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Aim of Merck Serono Ventures' fund

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here at BioTrinity 2011. On this show I have Roel Bulthuis, who is Head of Merck Serono Ventures, welcome to the show.

Roel Bulthuis:

Thank you.

Fintan Walton:

Merck Serono Ventures has a venture fund which was set up several years ago couple of years ago now you've been involved right from the very beginning, tell us what the aim of the Merck Serono Ventures is?

Roel Bulthuis:

Well we launched Merck Serono Ventures two-years ago so this is a March 2009 so it's little bit over two-years old with the aim to make strategic investments. So we are looking for companies that are developing products through our technologies that we could see as our business going forward, and since March of 2009 we've been making investments along those lines.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Roel Bulthuis

Head

Roel Bulthuis currently serves as Head of Merck Serono Ventures, the strategic venture capital group of Merck Serono SA Through the ventures group, Merck Serono is committed to actively invest in emerging biotech companies which have the potential to provide innovative products in Merck Serono's core therapeutic areas, or access to innovative technologies. In addition to the venture fund, Roel is also responsible for all 'externalization' transactions at Merck Serono, including 'fostering' deals, spin-offs and other alternative financing models. Roel joined Merck Serono in 2006 and is based in Geneva, Switzerland. Previously, Roel was a Director in the Biotech Investment Banking Team at Fortis Bank, where he was responsible for the origination and execution of a wide range of financing and strategic transactions in the biotech sector based out of Amsterdam and New York. Before joining Fortis Bank, Roel worked at Devgen NV in Gent, Belgium, as a business analyst. Roel holds a Msc. in Biopharmaceutical Sciences from Leiden University, the Netherlands, and an MBA in Finance from the Helsinki School of Economics, Finland.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

Merck Serono Ventures

Merck Serono Ventures is a strategic, corporate venture capital fund that invests in emerging biotechnology companies. The fund invests in biotech start-up companies that have the potential to provide innovative products in Merck Serono's core therapeutic areas, in particular in Neurodegenerative Diseases, Oncology, Autoimmune & Inflammatory Diseases, Endocrinology and Fertility. In addition, Merck Serono Ventures invests in companies developing innovative technologies that could enable the discovery and development of new products in Merck Serono's core therapeutic areas.